What are the measures to deal with the side effects of tepotinib? Adverse reaction management

Tepotinib , as a targeted therapy targeting MET exon 14 skipping mutations, has shown significant efficacy in the treatment of non-small cell lung cancer (NSCLC). However, it is also accompanied by certain adverse reactions. Especially during long-term medication, more attention needs to be paid to the management of drug tolerance and toxic side effects.

According to current clinical experience and international treatment guidelines, the most common adverse reactions of tepotinib include peripheral edema, nausea, vomiting, loss of appetite, fatigue, and mild to moderate liver function abnormalities. Among them, peripheral edema is one of the most common and bothersome side effects, which may affect patients' quality of life and compliance with ongoing treatment. To address this problem, symptoms can be alleviated by limiting salt intake, using moderate diuretics, and elevating the affected limb. In severe cases, the dosage can be adjusted or even discontinued for a short period of time.

In terms of liver function abnormalities, liver enzymes (ALT, AST) and bilirubin levels need to be monitored regularly, especially once every two weeks in the first two months of treatment, and then monthly. Once an abnormal increase occurs, suspension of medication or dose reduction may be considered, and the possibility of continued treatment shall be re-evaluated based on the recovery of liver function. For gastrointestinal reactions such as nausea and loss of appetite, appropriate dietary adjustments, electrolyte supplementation, and the application of antiemetic drugs can effectively alleviate them. At the same time, the patient's nutritional status should also be assessed and dietary intervention should be performed if necessary.

In addition, individualized medication guidance and symptomatic supportive treatment are key to managing the side effects of tepotinib. Each patient's constitution, underlying diseases, and drug resistance are different, so doctors should make dose adjustments or dressing decisions based on the patient's actual condition. At the same time, it is also very important to strengthen patient education to help patients identify early side effects and seek timely medical intervention, which can effectively reduce the risk of serious adverse events.

Reference materials:https://www.tepotinib.com/